Compare Baidu Inc (BIDU) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baidu Inc vs TG Therapeutics Inc — how do they compare? Baidu Inc trades at $105.12 (market cap $36.18B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Baidu Inc is far larger — about 4.7× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Baidu Inc nearer its low. Which is the better fit depends on your goals.
| BIDU | TGTX | |
|---|---|---|
Market Cap | $36.18B | $7.64B |
Sector | Media | Health |
52-Week High | $162.52 | $59.06 |
52-Week Low | $86.76 | $26.94 |
Enterprise Value | $32.81B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baidu (BIDU) trades at $104.41, down 4.65% today amid broader pressure on Chinese stocks. The stock shows a bearish technical signal, with recent earnings missing expectations in Q1 2026. Revenue declined to $129.08B in 2025, and net income margin compressed to 1.02%. However, analyst consensus remains strongly bullish with a $169.80 price target, and the company is advancing AI initiatives, including autonomous vehicle testing in London.
The outlook is mixed: strong analyst support and AI growth potential offer upside, but weak profitability, declining revenue, and macroeconomic risks in China pose significant challenges. Investors should weigh the high P/E of 78.19 against future AI-driven earnings acceleration.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baidu Inc
Baidu, Inc. operates an Internet search engine. The Company offers algorithmic search, enterprise search, news, MP3, and image searches, voice assistance, online storage, and navigation services. Baidu serves clients globally.
Read more on BIDU →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
